Aurobindo Pharma Limited — Updates, 23-04-2025: Press Release

Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma, has received USFDA approval for manufacturing Dasatinib Tablets in various dosages (20 mg to 140 mg). This product is bioequivalent to Bristol-Myers Squibb’s Sprycel Tablets and is expected to hit the market in Q1FY26. The anticipated market size is around US$ 1.8 billion for the year ending February 2025, presenting a significant opportunity. This approval marks the 181st ANDA approval for Eugia Pharma's facilities, focusing on oncology oral and sterile specialty products.

The approval enhances Aurobindo’s oncology portfolio and positions the company well in a lucrative market, highlighting its ongoing strategic focus on specialty pharmaceuticals. Investors should monitor this development closely, given the potential for substantial revenue growth in the oncology segment.